Prazepam
Prazepam is a long-acting benzodiazepine anxiolytic that potentiates the inhibitory neurotransmitter GABA at the GABA-A receptor by allosterically enhancing chloride ion conductance, producing anxiolytic, sedative, anticonvulsant, and muscle relaxant effects. It serves as a prodrug, being converted to the active metabolite desmethyldiazepam (nordazepam), and is used for the treatment of anxiety disorders.
Masse moléculaire
324,8000 g/mol
LogP
3,60
TPSA
32,70 Ų
Règle des 5 de Lipinski
Conforme
Mécanisme d'action
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Structure 2D
Cite this structure
Embed this structure
SMILES
O=C1CN=C(c2ccccc2)c2cc(Cl)ccc2N1CC1CC1
InChI
InChI=1S/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2
Molecular Formula
C19H17ClN2O
HBD / HBA
- / 2
Liaisons Rotatives
3
Atomes Lourds
23
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
Prazepam is a long-acting benzodiazepine anxiolytic that potentiates the inhibitory neurotransmitter GABA at the GABA-A receptor by allosterically enhancing chloride ion conductance, producing anxiolytic, sedative, anticonvulsant, and muscle relaxant effects. It serves as a prodrug, being converted to the active metabolite desmethyldiazepam (nordazepam), and is used for the treatment of anxiety disorders.
Reduces skeletal muscle tone and spasm through central or peripheral mechanisms, typically by modulating spinal reflexes, enhancing inhibitory neurotransmission, or blocking neuromuscular transmission.
Yes, Prazepam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL969. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 4890. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="prazepam"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/prazepam/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/prazepam/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/prazepam/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="prazepam"></drugfyi-drug>